Olaparib: an oral PARP | 合法藥品大搜索

olaparib做為單一療法或在含鉑化療之後施用，均證實會在體外抑制選定腫瘤細胞株的生長，並在人類癌症的小鼠異種移植模型減緩腫瘤生長。在缺乏BRCA以及非BRCA蛋白參與DNA ... Read More

Olaparib（LynparzaR，令癌莎）於2014年12月獲美國FDA核准，是全球第一個核准上市的poly ADP-ribose polymerase（PARP）抑制劑。台灣FDA於2018年6月核准olaparib， ... Read More

但就總存活期（overall survival）而言，於某次已有38%病患死亡的期中分析（interim analysis）的資料顯示，olaparib與安慰劑組並沒有明顯差別，危險比為0.94。Olaparib ... Read More

Olaparib（開發代號：AZD-2281、MK-7339，商品名：Lynparza、令癌莎）是抑制多ADP核糖聚合酶（PARP，一種參與DNA修復的酶）的藥物。它對具有遺傳性BRCA1或BRCA2突變的 ... Read More

由 J de Bono 著作 · 2020 · 被引用 398 次 — In men with metastatic castration-resistant prostate cancer who had BRCA1, BRCA2, or ATM mutations and who had disease progression while ... Read More

由 CC Gunderson 著作 · 2015 · 被引用 52 次 — Olaparib (Lynparza™; AZD2281) is a potent PARP-1 and PARP-2 inhibitor with biologic activity in ovarian cancer as well as other solid tumors. Read More

See full prescribing information for. LYNPARZA. LYNPARZA® (olaparib) tablets, for oral use. Initial U.S. Approval: 2014. --------- ... Read More

2020年7月15日 — Olaparib tablets are also used to help maintain the response of a certain type of pancreatic cancer that has not spread or progressed after the ... Read More

Olaparib is used as maintenance treatment in patients with advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer with a certain type ... Read More